Drug interactions
Linagliptin-metformin + Pasireotide
Severity: Major
Linagliptin-metformin and Pasireotide: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Pasireotide frequently causes hyperglycemia and can precipitate or worsen diabetes. This directly opposes the effect of metformin and linagliptin.
What this interaction means in plain words
Linagliptin-metformin and Pasireotide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Linagliptin-metformin belongs to Endocrine; Pasireotide belongs to Endocrine.
Why it happens
Pasireotide suppresses insulin and incretin (GLP-1, GIP) secretion, causing hyperglycemia.
What to do
Assess glycemic control before starting and monitor glucose frequently, intensifying antidiabetic therapy as needed. Metformin is the usual first-line option, and a GLP-1 agonist may be considered if control is inadequate.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Linagliptin-metformin and Pasireotide, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Linagliptin-metformin
Other interactions of Pasireotide
- Dronedarone + Pasireotide Contraindicated
- Pasireotide + Pimozide Contraindicated
- Amiodarone + Pasireotide Major
- Amisulpride + Pasireotide Major
- Amitriptyline + Pasireotide Major
- Anagrelide + Pasireotide Major
Frequently asked questions
Can I take Linagliptin-metformin with Pasireotide?
MediHelp rates the interaction as major. Linagliptin-metformin and Pasireotide can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Pasireotide frequently causes hyperglycemia and can precipitate or worsen diabetes. This directly opposes the effect of metformin and linagliptin.
How serious is the interaction between Linagliptin-metformin and Pasireotide?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Assess glycemic control before starting and monitor glucose frequently, intensifying antidiabetic therapy as needed. Metformin is the usual first-line option, and a GLP-1 agonist may be considered if control is inadequate.
What other medicines interact with Linagliptin-metformin?
MediHelp also lists interactions of Linagliptin-metformin with, for example, Apalutamide, Carbamazepine, Contrast media. The full list is on the Linagliptin-metformin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
